Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Aug 28, 26 | Macpherson Donald G | director | A-Award | 237 @ $136.98 | $32.50K |
| Aug 28, 26 |
| Lowery Frederick M. |
| director |
| A-Award |
| 283 @ $136.98 |
| $38.75K |
| Aug 28, 26 | Cutler Alexander M | director | A-Award | 365 @ $136.98 | $50.00K |
| Aug 25, 25 | Breen Edward D | director | G-Gift | 53,000 | — |
| Aug 17, 26 | Breen Edward D | director | G-Gift | 34,485 | — |
| Aug 6, 26 | Ferreira Beth | officer: President, Diversified Indstrl | F-InKind | 374 @ $146.38 | $54.71K |
| Aug 6, 26 | Barber Madeleine G | officer: VP Chief Accounting Officer | F-InKind | 101 @ $146.38 | $14.76K |
| May 31, 26 | Koch Lori | director, officer: CEO | F-InKind | 4,673 @ $48.03 | $224.4K |
Stock news · updated daily
DD expands its bioprocessing portfolio with AmberChrom SIL silica gel, targeting high-purity peptide purification amid growing demand for GLP-1 therapeutics.
Integrated Advisors Network LLC lifted its holdings in shares of DuPont de Nemours, Inc. (NYSE: DD) by 241.9% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,502 shares of the basic materials company's stock after buying an additional 4,600
New silica-based chromatography media helps biopharmaceutical manufacturers achieve demanding purity targets while supporting integrated purification workflows from crude purification through final polishing WILMINGTON, Del., Oct. 22, 2026 /PRNewswire/ -- DuPont (NYSE: DD) today announced the launch of DuPont™ AmberChrom™ SIL silica gel, a new reverse phase silica-based solution designed to support the purification and manufacture of peptide therapeutics, including glucagon-like peptide-1 ( GLP-1 ) receptor agonists.
Six industrial giants are selling off divisions while keeping payouts high, and the cash flow numbers behind those yields tell a very different story than the headline percentages suggest.
DuPont's innovation investments, healthcare acquisitions and productivity gains support growth as it raises 2026 earnings guidance amid persistent cost pressures.
Krilogy Financial LLC lifted its position in shares of DuPont de Nemours, Inc. (NYSE: DD) by 615.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 23,638 shares of the basic materials company's stock after purchasing an additional 20,333 shares during
WILMINGTON, Del., Oct. 13, 2026 /PRNewswire/ -- DuPont (NYSE: DD) today announced that its Board of Directors has declared a quarterly dividend of sixty cents ($0.60) per share on the outstanding Common Stock of the Company (par value $0.01 per share) payable on December 15, 2026, to holders of record of said stock at the close of business on November 30, 2026.
GAMMA Investing LLC lifted its position in DuPont de Nemours, Inc. (NYSE: DD) by 242.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 26,978 shares of the basic materials company's stock after buying an additional 19,096 shares during
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 4, 2026 | 1.76 | 1.88 | Beat 6.8% | $1.82B |
| May 5, 2026 | 0.49 | 1.65 | Beat 238.0% | $1.68B |
| Feb 10, 2026 | 1.29 | 1.38 | Beat 7.0% | $1.69B |
| Nov 6, 2025 | 0.47 | 3.27 | Beat 602.3% | $3.07B |
| Aug 5, 2025 | 0.45 | 0.47 | Beat 5.3% | $3.26B |
| May 2, 2025 | 0.96 | 3.09 | Beat 223.6% | $3.07B |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 8-K | Sep 10, 2026 | 2026-09-10 07:06:21 | View |
| 4 | Sep 1, 2026 | 2026-09-01 17:06:27 | View |
| 4 | Sep 1, 2026 | 2026-09-01 17:06:05 | View |
| 4 | Sep 1, 2026 | 2026-09-01 17:05:37 | View |
| 4 | Aug 19, 2026 | 2026-08-19 18:56:21 | View |
| 424B3 | Aug 12, 2026 | 2026-08-12 08:00:26 | View |
| EFFECT | Aug 11, 2026 | 2026-08-12 00:15:05 | View |
| 4 | Aug 10, 2026 | 2026-08-10 16:50:59 | View |
| 4 | Aug 10, 2026 | 2026-08-10 16:48:12 | View |
| SC 13G | Aug 7, 2026 | 2026-08-07 09:27:26 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | DD | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 296.7x | 7.4x · sector 16.6x | Elevated |
| Forward P/E (FY26E) | 18.8x | EPS est. 7.26 | Discount |
| Price / Book | 1.4x | 0.7x | Elevated |
| Price / Sales | 2.2x | 1.5x | Elevated |
| EV / EBITDA | 13.2x | 9.6x | Elevated |
| Return on equity | 0.3% | — | Weak |
| Gross margin | 34.4% | 31.0% | In line |
| Debt / Equity | 0.23 | 0.32 | Conservative |
| Piotroski / Altman Z | 8/9 | Z 0.57 | Distress |
Discounted cash flow model
1255 daily bars · split adjusted
FY2024 · 10-K disclosure
FY2025 · 10-K disclosure
Current price $136.55
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 15, 26 | RBC Capital | maintain | Outperform | Outperform |
| Oct 9, 26 | JP Morgan | downgrade | Overweight | Neutral |
| Oct 7, 26 | Citigroup | maintain | Buy | Buy |
| Oct 5, 26 | UBS | maintain | Buy | Buy |
| Aug 10, 26 | JP Morgan | maintain | Overweight | Overweight |
| Aug 7, 26 | RBC Capital | maintain | Outperform | Outperform |
| Aug 5, 26 | UBS | maintain | Buy | Buy |
| Jul 2, 26 | Citigroup | maintain | Buy | Buy |
| Jun 23, 26 | Morgan Stanley | maintain | Equal Weight | Equal Weight |
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 62.27 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 95.66 | Oscillator | Sell |
| Williams %R (14) | -0.94 | Oscillator | Sell |
| MACD (12, 26, 9) | 0.63 (Hist 0.81) | Oscillator | Strong Buy |
| Average Directional Index (14) | 13.38 (+DI 26.2 / -DI 18.1) | Trend | Neutral |
| EMA 20 | 131.92 | MA | Strong Buy |
| SMA 20 | 131.26 | MA | Strong Buy |
| EMA 50 | 132.88 | MA | Buy |
| SMA 50 | 132.48 | MA | Strong Buy |
| SMA 200 | 138.23 | MA | Sell |